BCR and acute lymphoblastic leukemia: Imatinib is a tyrosine kinase inhibitor directed against the BCR-ABL fusion enzyme, which is present in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoid leukemia (Ph+ ALL) [2–4].